Cathepsin L, a cysteine protease, is overexpressed in human tumor cells and plays a major role in melanoma progression. Our aim was herein to identify molecular mechanisms, which contribute to its overexpression. We found that cathepsin L protein expression correlated with mRNA level in tumor cells. Therefore, we focused on mechanisms involved in cathepsin L mRNA regulation. CpG island was localized in the 5 0 region of cathepsin L gene that encompassed regulatory regions identified as essential for promoter activity. CpG dinucleotides, not methylated in any melanoma cells analysed, were methylated in a B lymphoma cell line, which poorly express cathepsin L. Our data demonstrate that in lymphoma cells, cathepsin L silencing was methylationdependent. Furthermore, gene amplification was involved in cathepsin L overexpression in one melanoma cell line, while transcriptional mechanisms but not mRNA stability are responsible of cathepsin L overexpression in others melanoma cells. In addition, NF-Y, Sp1, Sp2 and Sp3 transcription factors, essential to basal cathepsin L transcription, are not directly involved in overexpression. Thus, our data provides the first demonstration that cathepsin L expression in tumor cells is under the control of distinct molecular mechanisms.
Introduction
Cathepsin L, a lysosomal cysteine endopeptidase widely expressed in human cells, is overexpressed in tumor cells (Turk et al., 2002) . We previously demonstrated that overexpression and secretion of procathepsin L in human melanoma cells increase their tumorigenicity and switch their phenotype from nonmetastatic to highly metastatic (Frade et al., 1998; Frade, 1999) . In addition, downregulation of cathepsin L expression by antisense cDNA significantly impaired malignancy property of glioma, myeloma and osteosarcoma cells (Kirschke et al., 2000; Krueger et al., 2001; Levicar et al., 2003) .
While lysosomal cathepsin L processes intracellular proteins, secreted procathepsin L regulates function of extracellular proteins. For instance, procathepsin L secreted by human melanoma cells cleaved human C3, the third component of complement, thus inhibiting complement-mediated cell lysis (Jean et al., 1995 (Jean et al., , 1996 (Jean et al., , 1997 . In addition, secreted procathepsin L increased tumor cells invasiveness by mediating degradation of extracellular matrix components (Ishidoh et al., 1997; Krueger et al., 2001; Levicar et al., 2003) . Cathepsin L was also identified as an interleukin-8 converting enzyme (Ohashi et al., 2003) . Interleukin-8 contributes to human melanoma progression by acting as a mitogenic and angiogenic factor (Huang et al., 2002) .
Thus, the clear demonstration that overexpression and secretion of procathepsin L are directly associated to tumorigenic and metastatic processes, point out two complementary analysis. The first was to control procathepsin L secretion. For this purpose, we generated an anti-cathepsin L single chain variable fragment (ScFv) (Guillaume- Rousselet et al., 2002) . We demonstrated that its intracellular expression in human melanoma cells inhibits procathepsin L secretion and also the tumorigenic and metastatic phenotype of human melanoma cells in nude mice (Rousselet et al., 2004) . The second was to elucidate the mechanisms involved in regulation of expression of the gene encoding human cathepsin L. Human cathepsin L gene was localized on human chromosome 9q21-22 (Chauhan et al., 1993) . However, until recently, transcriptional regulation of human cathepsin L gene was not elucidated. We recently determined the sequence of the 5 0 -flanking region of the human cathepsin L gene up to 3263 bp upstream from the translation start site and localized transcription initiation sites. We also identified regulatory sites essential for cathepsin L promoter activity in a 50 bp region, containing one CCAAT motif and two GC boxes, on which bound NF-Y (nuclear factor Y) and Sp1 and Sp3 transcription factors, respectively . This region is located 60 bp from the major transcription initiation site. Involvement of Sp1 and Sp3 in cathepsin L promoter regulation was confirmed more recently in granulosa and Sertoli cells (Charron et al., 2003; Sriraman and Richards, 2004) .
Thus, we herein analysed mechanisms which may be involved in regulation of human cathepsin L gene in tumor cells. Our data support cathepsin L expression in tumor cells is under the control of distinct molecular mechanisms.
Materials and methods

Cell culture
Four human melanoma cell lines, phenotyped in nude mice and kindly provided by Dr M Bar-Eli (MD Anderson Cancer Center, Houston, TX, USA), were herein used: A375SM and DM-4 cells (highly metastatic), DX-3 cells (low metastatic) and SB-2 cells (nonmetastatic) (Luca and Bar-Eli, 1998) . Raji, a human B cell line established from a Burkitt's lymphoma was also used. Melanoma and Raji cells were grown as previously described (Barel et al., 1989; Jean et al., 2002) . Actinomycin D and 5-aza-2 0 -deoxycitidine (5-aza-dC) (Sigma) were added to cell cultures at a final concentration of 10 mg/ml and 5 mM, respectively. Culture medium was changed with medium containing freshly added 5-aza-dC on the third day of culture and every 24 h between the third and the sixth day.
Cathepsin L expression analysis
To estimate cathepsin L mRNA expression, semi-quantitative reverse transcription-PCRs were performed as previously described (Rousselet et al., 2004) . To determine cathepsin L protein expression and secretion, immunoblot assays were performed using anti-cathepsin L moAb (clone 3D8) (Guillaume- Rousselet et al., 2002) . Cathepsin L-specific activity was measured by using the synthetic substrate Z-Phe-Arg-7-amido-4-methylcoumarin (Z-Phe-Arg-AMC, Calbiochem) in condition described by Kamboj et al. (1993) .
Transcription factors analysis EMSA analysis was performed as previously described . The following antibodies were used in immunoblot and supershift analysis: anti-CTF/NF1, anti-Sp2, anti-Sp3 and anti-Sp4 polyclonal Ab (Santa Cruz Biotechnology) and anti-Sp1 polyclonal Ab (Active Motif).
Transfection and reporter assays
The plasmid cathepsin L promoter-luciferase constructs pGL3-PCL-(À1/À3263), pGL3-PCL-(À1/À2273) and pGL3-PCL-(À1/À1646) have been described previously . Transfections of melanoma cells were performed with 600 ng of pGL3 vector reporter constructs and 200 ng of phRL-null (Promega) or 10 ng of pRL-CMV using Lipofectin reagent (Invitrogen). Transfection of Raji and A375SM cells were carried out by electroporation. Cells (10 6 ) were incubated with 30 mg of pGL3 and 5 mg of phRL-null in RPMI 1640 medium for 5 min and subjected to electroporation at 300 V and 950 mmicrofarads. After incubating for 10 min at 41C, the transfected cells were transferred into culture medium. Cell extracts were prepared 48 h after transfection and luciferase activities were measured with the Dual-Luciferase Reporter Assay System (Promega). The relative firefly luciferase activity was calculated by normalizing transfection efficiency with the Renilla luciferase activity.
Gene amplification analysis
Genomic DNA was isolated from melanoma cells using Qiagen genomic-tip (Qiagen). Semi-quantitative PCR analysis was carried out with 28 cycles (941C, 30 s; 581C, 1 min; 721C, 1 min) using specific primers: 5 0 -CACAGTGGGGTAGCT GGCTGCTGAGGCAAT-3 0 and 5 0 -TTTGAGCCAGACTG TAGC-3 0 for cathepsin L; and 5 0 -GGCACCCCCAAAGTA TTTAGTG-3 0 and 5 0 -ATGGTCCGACTATCCAGTTCA-3 0 for RB18A. PCR products were analysed on agarose gel containing ethidium bromide. For Southern blot analysis, genomic DNA (15 mg) was digested with HindIII, size-fractionated on agarose gel and transferred to a Hybond-N þ membrane (Amersham). The membrane was hybridized with a fluorescein-labelled cathepsin L probe generated by PCR from genomic DNA with primers 5 0 -CTCATAAAACAGAGG TTCCTGGAACACTTT-3 0 and 5 0 -ACTCTAACATTTGATC ACAGTTTAGAGGCA-3 0 . Detection was performed using Gene Images CDP-Star detection module (Amersham).
Bisulfite genomic sequencing Genomic DNA, digested by EcoRI, was denatured in NaOH and treated with a solution containing sodium bisulfite and hydroquinone (Sigma). The reaction was overlaid with mineral oil and incubated in the dark at 551C for 16 h. The desulfonation reaction was completed by incubating the bisulfite-treated DNA with NaOH for 15 min at 371C. Three nested PCRs were realized to analyse the methylation status of the À583/À2164 region of cathepsin L promoter using primers based on the predicted sequence after bisulfite conversion (Table 1) . Primary and nested PCR reactions were carried out with 35 cycles (941C, 30 s; 551C, 60 s; 721C, 60 s). PCR products were purified and were subcloned in pcDNA3 (Invitrogen). After transformation, individual colonies were picked, plasmids were prepared and cloned PCR products were sequenced by Genome Express.
Plasmid CpG and CCWGG methylation
In vitro CpG methylation was performed using SssI methylase (New England Biolabs). DNA fragments of the human cathepsin L promoter corresponding to regions À1/À1646 and À1/À2273 were generated by PCR using primers previously described . The agarose-gelpurified PCR products were incubated without (mock methylated) or with SssI methylase. The completeness of the methylation reaction was monitored by digestion of an aliquot with the 5-methyl-cytosine-sensitive restriction enzyme SmaI. Fragments were then ligated in pGL3-Basic (Promega). Purified ligation products were monitored by agarose gel electrophoresis and transfected into A375SM cells. To analyse CCWGG methylation, reporter vectors were propagated in dcmÀ and dcm þ Escherichia coli as described (Malone et al., 2001 ) and were isolated from bacteria culture.
Results
Cathepsin L expression and promoter activity in human lymphoma and melanoma cells Cathepsin L mRNA and protein expressions were analysed in four human melanoma cell lines and a human B lymphoma cell line (Raji). Cathepsin L intracellular expression and secretion were studied in cell extracts ( Figure 1a ) and in conditioned media (Figure 1b) , respectively, by Western blot using anticathepsin L moAb. A375SM and DM-4 melanoma cells, characterized by high tumorigenic and metastatic phenotype in nude mice (Luca and Bar-Eli, 1998) , showed high level of expression and secretion of cathepsin L and procathepsin L, respectively ( Figure  1a and b, lanes 1 and 2). SB-2 and DX-3 melanoma cells, characterized by a low tumorigenic and low metastatic phenotype (Luca and Bar-Eli, 1998) , expressed and secreted low amount of cathepsin L and procathepsin L, respectively ( Figure 1a and b, lanes 3 and 4). The patterns of intracellular 41 kDa procathepsin L, 34 and 29 kDa cathepsin L mature forms were different between these four cells ( Figure 1a, lanes 1-4) . In the extracellular medium, only the 41 kDa procathepsin L form was detected (Figure 1b, lanes 1-4) . Analysis of cathepsin L mRNA by semi-quantitative RT-PCR using specific primers (Figure 1c ), demonstrated higher 
Positions are indicated relative to the translational start codon of cathepsin L gene. The underlined restriction sites were added to the 5 0 -end of nested primers to facilitate subcloning. For Raji, the human B lymphoma cell line, the amounts of cathepsin L mRNA and protein were so low, as compared to melanoma cells, that it was necessary to modify the experimental conditions, that is, to increase the number of amplification cycle during the PCR and to load a higher amount of protein on SDS-PAGE for Western blot analysis ( Figure 1a , b and c, lane 5). In control, levels of GAPDH mRNA and protein were identical in the four melanoma cells analysed in the same experimental conditions. However, GAPDH mRNA and protein levels shown in Figure 1a and c were higher in Raji cells since, as explained above, it was necessary to modify the experimental conditions to allow cathepsin L detection.
We next compared cathepsin L promoter activity between melanoma and Raji cells. The pGL3-PCL-(À1/À1646) construct contained the luciferase gene driven by the 1646 bp sequence upstream of the translation start site of the cathepsin L gene. pGL3-PCL-(À1/À1646) vector was transfected into cells with the promoterless phRLnull plasmid, used as an internal control to measure the transfection efficiency. Promoter activity was analysed with the Dual-Luciferase Reporter System. Data demonstrated that cathepsin L promoter activity was not significantly different between DM-4, DX-3 and SB-2 cells but was higher in A375SM cells ( Figure 1d ). Despite cathepsin L expression was very low in Raji cells, relative luciferase activity in these cells was higher than in A375SM cells ( Figure 1e ). Altogether, these data suggested that, while a good correlation exists between cathepsin L mRNA and protein expression in human tumor cells: (1) cathepsin L overexpression in A375SM human melanoma cells was regulated by a transcriptional mechanism at the promoter level; (2) other mechanisms are involved in high and low expression of cathepsin L in DM-4 cells and in DX-3, SB2 or Raji cells, respectively.
Analysis of NF-Y and Sp-family members DNA binding activities and expression in melanoma cells
As we previously demonstrated that Sp1, Sp3 and NF-Y transcription factors which bind GC boxes and CCAAT motif, are important for cathepsin L gene transcription , we analysed their involvement in A375SM and DX-3 or SB-2 melanoma cells characterized by a high and low level of cathepsin L expression, respectively. For this purpose, EMSA analysis were performed by incubating radiolabelled oligonucleotides containing cathepsin L CCAAT motif (Figure 2a Members of Sp-family of transcription factors present in DNA-protein complexes obtained with cathepsin L GC box, were identified by supershift using specific antiSp1, -Sp2, -Sp3 and -Sp4 Abs (Figure 2c ). In agreement with our previous data , complex 1 was identified as containing Sp1 (lane 2) and complexes 2 and 3 as containing two Sp3 species of different mobility (lane 4). In addition, we herein found that Sp2 transcription factor bind to cathepsin L GC box. 
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Indeed, complex 1 was also supershifted by Sp2-specific Ab demonstrating that complex 1 contained both Sp1 and Sp2, transcription factors (lane 3). The specificity of these interactions was supported by the absence of complexes containing Sp4 (lane 5) or CTF/NF1 (lane 1), as controlled using specific Abs. Identical patterns were obtained with nuclear extracts of the three melanoma cell lines.
It is well established that transcriptional regulation by members of Sp-family transcription factors is complex and depends of the isoforms expressed and of the ratio between each members (Suske, 1999) . Thus, we measured Sp-family protein expression levels. For this purpose, Western blots were performed on nuclear extracts (Figure 2d ) prepared from A375SM (lane 1), DX-3 (lane 2), and SB-2 (lane 3) cells. A single immunoreactive complex was detected using anti-Sp1 Ab and anti-Sp2 Ab characterized by molecular masses of 105 and 80 kDa, respectively. Using anti-Sp3 Ab, four complexes were detected. These complexes contained two doublets with molecular masses of 115 and 70 kDa. Levels of Sp1, Sp2 and Sp3 protein expression and ratio of Sp3 isoforms were similar in all melanoma cells tested. Altogether, these data demonstrated that binding activities of NF-Y, Sp1, Sp2 and Sp3 transcription factors were similar in all the melanoma cells tested and independent of the level of cathepsin L expression. These transcription factors are not directly responsible for the differences of cathepsin L expression in melanoma cell lines.
Gene amplification of cathepsin L in human melanoma cells Cathepsin L gene amplification was analysed in melanoma cells. For this purpose, semi-quantitative PCR was performed using specific primers of cathepsin L on genomic DNAs. Figure 3a shown a representative gel analysis of three independent PCR experiments using three different preparations of genomic DNA extracted from melanoma cells. As expected, PCR products obtained with the four melanoma cells were caracterized by a size of 716 bp. Intensity of the 716 bp band was significantly stronger in DM-4 cells (lane 2) than in other melanoma cells (lanes 1, 3 and 4), which is representative of the presence of multiple cathepsin L gene copy in DM-4 cells. As control, RB18A gene, localized on a different chromosome (Frade et al., 2000) and amplified from the same genomic DNA samples, did not present significant differences in its amplification between these melanoma cells. In addition, Southern blot analysis was also performed using a probe corresponding to genomic sequence from Exon 2 to Exon 4 of cathepsin L gene (Figure 3b) . Database of the National Center for Biotechnology Information (NCBI) indicated that this probe should detect a genomic DNA fragment of 2845 bp after digestion by HindIII. A single band of 2.9 kb was detected for the four melanoma cells suggesting no chromosomic rearrangement between these two HindIII restriction sites. Band was more intense on DM-4 cells (lane 2) than on the other melanoma cells (lanes 1, 3 and 4) . Densitometric analysis of Southern blot autoradiographs indicated that the cathepsin L gene copy number of DM-4 cells was two times higher than in other melanoma cells. These data demonstrated that cathepsin L ovexpression in DM-4 human melanoma cells was more likely due to gene amplification and not to transcriptionnal regulation at the promoter level as in A375SM cells.
mRNA stability in human melanoma cells mRNA stability in human melanoma cells was analysed by treating cells with actinomycin D, an inhibitor of mRNA transcription. Expression of cathepsin L mRNA was analysed by semi-quantitative RT-PCR using specific primers of cathepsin L (Figure 4) . mRNA expression in actinomycin/D treated A375SM (highly metastatic) and DX-3 (low metastatic) cells decreased by 40% after 3 h and was not detectable after 7 h. The absence of significant difference in mRNA stability between these two cells, suggested that mRNA stability was not involved in cathepsin L overexpression. 
Role of methylation of cathepsin L promoter in cathepsin L expression Sequence analysis demonstrates that the À609 to À2111 region of cathepsin L promoter contains a CpG island. This region is characterized by a 63% C þ G content and 106 CpG sites ( Figure 5 ). Presence of CpG island (as defined by Gardiner-Garden and Frommer, 1987) was also confirmed using WWWCPG program at WebGene (www.itba.mi.cnr.it/webgene/). The transcription initiation sites and the regulatory region containing the CCAAT motif and the two GC boxes, previously identified by us as essential for cathepsin L transcription were localized in this CpG island (Figure 5a ). The presence of the CpG island led us to analyse CpG methylation in cathepsin L promoter. For this purpose, in vivo methylation status of the À609/À2111 region was analysed using the bisulfite genomic-sequencing technique on lymphoma and melanoma cells. The modified DNA was amplified using three sets of primers and the complete CpG island sequence was analysed. Data demonstrated that all unmethylated cytosine residues in the original sequence were converted to thymidine residues demonstrating the completeness of the bisulfite conversion. As summarized in Table 2 , the À609/À2111 region of cathepsin L promoter contains methylated cytosine residues in most of the CpG dinucleotides in Raji, the lymphoma cells. Among the 106 CpG sites, only 15 were partially methylated (CpG positions: 12, 13, 17, 19, 25, 40, 59, 60, 70, 75, 84, 88, 94, 96 and 102) and three completely unmethylated (CpG positions: 57, 89, 95). At the opposite, cytosine residues were not methylated in the four melanoma cells, except partial methylation in 5 0 and 3 0 of the CpG island. These data suggested that in Raji cells, but not in melanoma cells, low expression of cathepsin L was related to the methylation status of the CpG island.
Thus, to verify that DNA methylation of the CpG island inhibits cathepsin L promoter activity, we performed in vitro methylation using the enzyme SssI methylase, which methylated all CpG dinucleotides. Experiments were performed using two reporter vectors which contained the luciferase reporter gene driven by human cathepsin L promoter segments: one which had the strongest promoter activity pGL3-PCL-(À1/À1646) and one which had the full CpG island pGL3-PCL-(À1/À2273). The À1/À1646 and the À1/À2273 segments of cathepsin L promoter were generated by PCR, either methylated or mock-methylated with SssI methylase, then ligated in the pGL3-Basic reporter vector. Subsequently, A375SM cells were transfected with the methylated or unmethylated plasmids, and promoter activity was determined (Figure 6a ). SssI methylation in both cathepsin L promoter constructs dramatically decreased the promoter activity by 90 and 100% for pGL3-PCL-(À1/À2273) and pGL3-PCL-(À1/À1646), respectively. Reporter gene assays revealed that methylation of the cathepsin L promoter by SssI methylase leads to an almost complete loss of transcriptional activity. We also analysed regulation of cathepsin L promoter by C m CWGG DNA methylation which was described in mammalian cells (Malone et al., 2001) . Indeed, cathepsin L promoter (3263 bp upstream the translational site) contained 20 C m CWGG potential methylation sites, one close to the À1545/À1550 GC box. The Dcm methylase of E. coli methylates specifically the internal cytosine residue of the C m CWGG sequences. Reporter constructs pGL3-PCL-(À1/À1646) and pGL3-PCL-(À1/À3263) were propagated in dcmDH5a or dcm þ BL21 E. coli. After transfection in A375SM cells, luciferase activity was measured (Figure 6b) . Results demonstrated that the C m CWGGmethylated cathepsin L promoter had the same activity than the C m CWGG-unmethylated promoter in both constructs. Thus, these data demonstrated that cathepsin L promoter activity could be regulated by CpG methylation.
Furthermore, we analysed whether expression of cathepsin L gene could be restored in cells treated with 5-aza-2 0 -deoxycitidine (5-aza-dC), a demethylating agent known to reduce levels of DNA methylation and to increase expression of genes silenced by DNA methylation. Raji lymphoma and A375SM melnoma cells were treated with 5-aza-dC at concentration of 5 mM for a 3-7 day period. Total RNAs were isolated and RT-PCRs were performed using specific primers of cathepsin L cDNA and GAPDH cDNA. As shown Figure 7a , a 6 days treatment with 5-aza-dC induced in Raji cells, in which cathepsin L promoter was methylated, a strong increased of cathepsin L cDNA expression, while in opposite, even after 7 days of the same treatment of A375SM cells, in which the cathepsin L promoter was unmethylated, cathepsin L cDNA 45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65  66  À1456 À1447 À1441 À1433 À1429 À1416 À1413 À1410 À1390 À1367 À1365 À1361 À1334 À1328 À1319 À1289 À1267 À1265 À1259 À1257 À1243 67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  À1222 À1205 À1194 À1192 À1189 À1187 À1184 À1167 À1142 À1138 À1128 À1113 À1107 À1090 À1071 À1065 À1054 À1043 À1002 À1000 À996 effect of 5-aza-dC was time-dependent as a significant increase in cathepsin L expression and activity was observed between 6 and 7 days treatment. Thus, 5-azadC treatment activate cathepsin L transcription in Raji cells. All together, these data demonstrated that the silencing of cathepsin L was methylation-dependent in these cells.
Discussion
Our previous demonstration that human melanoma cells characterized by high tumorigenic and metastatic phenotype overexpress and secrete procathepsin L (Frade et al., 1998; Frade, 1999; Rousselet et al., 2004) , led us to analyse the mechanisms which may be involved in regulation of human cathepsin L expression. This study was performed on four human melanoma cell lines A375SM and DM-4 (two high-expressing cathepsin L) and DX-3 and SB-2 (two low-expressing, cathepsin L) and a lymphoma cell line, Raji (poorly expressing cathepsin L).
First, differences were found on the regulation of cathepsin L expression between A375SM and DM-4, the two melanoma cells highly expressing cathepsin L.
Indeed, cathepsin L overexpression was regulated by transcriptional mechanism at the promoter level in A375SM cells but not in DM-4 cells. Indeed, the low activity of cathepsin L promoter in DM-4 cells was similar to the one of DX-3 and SB-2, two cell lines which expressed low amount of cathepsin L. Furthermore, we demonstrated that DM-4 cells carry higher copy number of cathepsin L gene than A375SM cells. Gene amplification have been also described as a mechanism of overexpression in tumor cells of cathepsin B, an other member of the lysosomal cysteine endopeptidase family (Hughes et al., 1998; Abdollahi et al., 1999) . In addition, an increase of copy number of the cathepsin L gene was described in two glioblastoma multiforme, characterized by chromosome aberrations (Mao and Hamoudi, 2000) .
Second, our data supported that differences in cathepsin L expression between the four human melanoma cells was not due to mRNA stability. This is also supported by the structure of the 3 0 -untranslated region (3 0 -UTR) of cathepsin L mRNA. Indeed, presence of sequence determinant elements which reside mainly in the 3 0 -UTR of mRNA were associated to changes in mRNA stability (Grzybowska et al., 2001) . Analysis of the human expressed sequence tag (EST) database (Megablast; National Centre for Biotechnology Information) allowed to estimate that the length of the 3 0 -UTR of cathepsin L mRNA is 285 bp. A polyadenylation signal (AAUAAA sequence) is localized 263 bp downstream the codon stop. Sequence analysis of the 3 0 -UTR using the UTRScan program (Pesole and Liuni, 1999) revealed that this short 3 0 -UTR did not contain any regulatory sequence elements involved in mRNA stability such as adenylate/uridylate-rich elements (AREs).
Third, we previously identified NF-Y and Sp1 and Sp3 as transcription factors involved in the regulation of human cathepsin L gene transcription . In addition, we herein demonstrated that Sp2 but not Sp4 bind also to GC box in melanoma cells. However, our data did not support that NF-Y and members of Sptranscription factor family are directly involved in cathepsin L overexpression in A375SM and DM-4 cells, as compared to DX-3 and SB-2 cells. Indeed, no differences were observed in NF-Y binding to the CCAAT motif and in Sp1, Sp2 or Sp3 to the GC box between melanoma cells. Furthermore, Sp1, Sp2 and Sp3 are expressed at the same level and with the same ratio. However, the possibility that transcriptional coactivators of NF-Y or Sp-family member may mediate cathepsin L overexpression in A375SM cells, could not be ruled out and further studies are needed. Interestingly, two other transcription factors were described to regulate cathepsin L transcription in rat: CREB and Egr-1 (Ishidoh et al., 1997; Sriraman and Richards, 2004) . Sequence alignment and analysis with MatInspector v2.2 program using TRANSFAC 4.0 database of potential transcription factor binding sites, show that the CCAAT motif and the two GC boxes are conserved between human and rodent but the CREB binding site is lost in human cells. In addition, while it was described that Egr-1 binding site overlap the GC box closer of the transcription initiation site, we did not observe binding of Egr-1 on this proximal GC box in human melanoma cells . Interestingly, it was described that Egr-1 was involved in cathepsin L expression regulation under both genetic and metabolic stress conditions in human carcinoma cells (Amuthan et al., 2001) . These data suggest that specific regulation of Egr-1 binding on cathepsin L promoter could be triggered under conditions others than normal culture conditions. Fourth, post-transcriptional mechanisms may also regulate cathepsin L expression. Indeed, data demonstrated that the ratio between the intracellular forms of cathepsin L was different between these four melanoma cell lines. Procathepsin L (41 kDa) is proteolysed first to a single-chain form (34 kDa) and then to a double-chain Figure 7 Effect of 5-aza-dC treatment on cathepsin L expression. (a) Raji cells were treated with or without 5 mM 5-aza-dC for 3 days (lanes 1 and 2) or 6 days (lanes 3 and 4), A375SM cells for 5 days (lanes 5 and 6) or 7 days (lanes 7 and 8). CDNA were prepared and were PCR amplified with primers specific of cathepsin L (30 and 22 cycles of amplification for Raji cells and A375SM cells, respectively) or GAPDH (22 cycles). Quantification of each band was determined using NIH Image software. Cathepsin L band intensities were normalized to GAPDH controls and compared to the band intensity obtained with untreated cells. (b) Total extracts (240 mg) prepared from Raji cells (lanes 1-4) or total extracts (30 mg) prepared from A375SM cells (lanes 5 and 6) treated with or without 5 mM 5-aza-dC for 6 days (lanes 1 and 2) or 7 days (lanes 3-6) were submitted to SDS-PAGE. Western blot were performed with anti-cathepsin L and anti-GAPDH moAbs. (c) Cathepsin L activity was measured using the fluorogenic substrate Z-Phe-Arg-AMC using Raji cell extracts treated or untreated with 5 mM 5-aza-dC.
Regulation of cathepsin L expression in human tumor cells D Jean et al form (with a heavy chain of 29 kDa) in lysosome. Involvement of post-traductional regulatory mechanism was also supported by changes in ratio between cathepsin L forms described in epidermis under pathological conditions (Kawada et al., 1997) .
Fifth, we identified a CpG island in the 5 0 region of cathepsin L gene from À609 to À2111 bp of the translation start site. This CpG island encompassed regulatory regions, previously identified by us as essential for cathepsin L promoter activity . Presence of a CpG Island in the human cathepsin L promoter suggested that its activity could be controlled by methylation of the cytosine residues as described in several G/C-rich promoters. We herein demonstrated that cytosine residues in all CpG dinucleotides in the À583/À2164 region of cathepsin L promoter are methylated in genomic DNA from Raji, the lymphoma cell line, in which the gene is mainly silent. In opposite, almost none of the cytosine residues was methylated in CpG dinucleotides from the same region in melanoma cells. In addition, in vitro methylation of CpG sites in the cathepsin L promoter reduces the promoter activity in a transient transfection assay in melanoma cells. Repression of the cathepsin L gene expression by methylation in Raji cells is inhibited by treatment of these cells by DNA demethylating agent 5-aza-C. Thus, all together, our data clearly demonstrated that cathepsin L promoter activity is regulated by CpG methylation and that low expression in Raji cells is obviously related to DNA methylation. Thus, these data allowed to identify a new mechanism that regulates cathepsin L expression and constitutes the first demonstration that expression of a lysosomal cysteine endopeptidase is regulated by CpG methylation.
Methylation of non-CpG cytosine was recently described in mammalian cells. C m CWGG DNA methylation was involved in B cell lymphoma gene silencing (Malone et al., 2001) . Some promoter, as the one of the TP53 gene in acute lymphoblastic leukemia, could be inhibited by methylation on both CpG dinucleotides or on CCWGG motif (Agirre et al., 2003) . We analysed effect of C m CWGG methylation on cathepsin L promoter activity using reporter constructs propagated in dcmÀ or dcm þ E. coli strain as described by others (Malone et al., 2001) . Despite, cathepsin L promoter (3263 bp upstream the translational site) contain 20 C m CWGG potential methylation sites, one close to the À1545/À1550 GC box, C m CWGG methylation did not modify cathepsin L promoter activity in melanoma cells.
In conclusion, these results provide evidences that several distinct molecular mechanisms regulated cathepsin L expression in melanoma and lymphoma cells. Thus, attempts to inhibit cathepsin L expression in human cancer need specific strategies for each case.
